Researchers Determine Best Predictors of Acromegaly Remission Following Transsphenoidal Surgery

Tumor size and random growth hormone concentration at diagnosis are the best predictors for remission of acromegaly after transsphenoidal surgery (TSS), according to a study recently published in The Journal of Clinical Endocrinology & Metabolism.

Researchers led by Eva C. Coopmans, MD, of Erasmus University Medical Center in Rotterdam, The Netherlands, point out that TSS is the primary treatment of choice for acromegaly, since it’s the only treatment that can provide a cure and results in lower lifetime costs. “Overall, approximately 75% of patients achieve long-term remission, which sometimes takes several years after initial surgery,” the authors write. “It is important to identify patients in whom surgical remission is not attainable at an early stage, both to inform patients on expected treatment outcome and to select those who are more likely to need additional therapy.”

In this large multicenter study, the researchers analyzed clinical data since 2000 from 282 patients across three tertiary neurosurgical referral centers in The Netherlands. They found that early biochemical remission is best distinguished by maximum tumor diameter at diagnosis and long-term remission occurs more frequently in patients with a lower random GH concentration at diagnosis who harbor a smaller tumor. “Relapse after TSS occurred more frequently in patients who were younger at diagnosis and harbored larger tumors that secrete more GH,” the authors write. “This observation confirms and builds upon previous studies, proposing age at diagnosis to be a clinical marker of tumor size and aggressiveness.”

The authors go on to write that these predictors can be used to better inform patients on expected treatment outcome and to personalize postoperative treatment and follow-up. “In addition,” they conclude, further optimization of surgical techniques to improve remission rates for patients who harbor large tumors extending laterally into the cavernous sinus is warranted.”

You may also like

  • Phase III LINC 4 Study Confirms Efficacy and Safety of Osilodrostat in Patients with Cushing’s Disease

    Positive results from the Phase III LINC 4 study have confirmed the efficacy and safety of osilodrostat, an oral therapy for patients with Cushing’s disease. The results were published in The Journal of Clinical Endocrinology & Metabolism. Recordati Rare Diseases is marketing the drug as ISTURISA®. The LINC 4 study augments the efficacy and safety…

  • Rare But Devastating: Keeping Track of Acromegaly Cases

    Since acromegaly is such a rare disorder, when an endocrinologist is presented with a potential case, the most accurate and complete data available would be a helpful tool. Endocrine News takes a closer look at how the Mexican Acromegaly Registry has helped endocrinologists address the issues patients with acromegaly face, both physically and financially.  …